SCHEMBL2011515

SCHEMBL2011515

O=S(=O)(NCCCCO)c1ccccc1-c1ccccc1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.56
FABP4 P15090 1/20 0.46
ALOX5AP P20292 3/20 0.46
FEN1 P39748 3/20 0.46
ALDH1A1 P00352 4/20 0.44
LMNA P02545 2/20 0.44
THRB P10828 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CA12 O43570 2/20 0.44
CA9 Q16790 2/20 0.44
KDM4E B2RXH2 2/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LPAR2 Q9HBW0 2/20 0.41
SCN1A P35498 2/20 0.41
SCN2A Q99250 2/20 0.41
SCN3A Q9NY46 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12571016 0.88 RECQL (0.70) RECQLFABP4ALDH1A1LMNATHRB
SCHEMBL15915929 0.87 RECQL (0.73) RECQLFABP4ALOX5APFEN1ALDH1A1
SCHEMBL15915973 0.87 RECQL (0.73) RECQLFABP4ALOX5APFEN1ALDH1A1
SCHEMBL15915838 0.83 RECQL (0.68) RECQLFABP4ALDH1A1LMNACA12
SCHEMBL15924985 0.82 FEN1 (0.55) RECQLALOX5APFEN1ALDH1A1LMNA
SCHEMBL2007223 0.79 FEN1 (0.58) FABP4ALOX5APFEN1ALDH1A1LMNA
SCHEMBL15916047 0.77 RECQL (0.62) RECQLFABP4ALDH1A1CA12CA9
SCHEMBL5503781 0.75 GBA1 (0.51) RECQLFABP4ALOX5APFEN1ALDH1A1
SCHEMBL4060764 0.72 ALDH1A1 (0.79) ALDH1A1LMNAKDM4EPKMSMN1; SMN2
SCHEMBL18319951 0.71 KMT2A (0.60) ALDH1A1LMNATHRBCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964643-B2 Biphenyl-4-sulfonic acid-(4-hydroxybutyl)-amide and derivatives; inhibits osteoclast survival, formation, and/or activity and/or inhibits bone resorption; osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, antiinflammatory, -carcinogenic agents; immunostimulants THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2011-06-21 US disclosed
EP-1756046-B1 ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS UNIV ABERDEEN (GB) 2009-12-09 EP disclosed
US-20080119555-A1 Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119555-A1 Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions ARSA, CNKSR1, BCL9L RECQL 1727/4885FABP4 3203/4885ALOX5AP 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.